{"pub_date": "2016-03-11T00:00:00Z", "subsection_name": "DealBook", "lead_paragraph": "Teva\u2019s $40.5 billion deal for the generic drug business of Allergan was approved after they agreed to sell some operations to ease antitrust concerns.", "print_page": "2", "document_type": "article", "byline": {"person": [{"rank": 1, "organization": "", "lastname": "BRAY", "firstname": "Chad", "role": "reported"}], "original": "By CHAD BRAY"}, "multimedia": [], "section_name": "Business Day", "headline": {"print_headline": "Business Briefing; Europe Approves Teva Deal to Buy Allergan Generics", "main": "E.U. Approves Teva-Allergan Deal With Conditions"}, "source": "The New York Times", "blog": [], "word_count": "260", "web_url": "http://www.nytimes.com/2016/03/11/business/dealbook/eu-approves-teva-allergan-deal-with-conditions.html", "slideshow_credits": null, "news_desk": "Business", "type_of_material": "News", "snippet": "Teva\u2019s $40.5 billion deal for the generic drug business of Allergan was approved after they agreed to sell some operations to ease antitrust concerns.", "_id": "56e196a438f0d80718d56abb", "abstract": "European Union approves $40.5 billion sale of Allergan to Teva Pharmaceutical Industries after companies agreed to sell some businesses; United States still needs to approve deal. ", "keywords": [{"rank": "1", "name": "organizations", "value": "Teva Pharmaceutical Industries Ltd", "is_major": "Y"}, {"rank": "2", "name": "organizations", "value": "Allergan Inc", "is_major": "Y"}, {"rank": "3", "name": "organizations", "value": "European Union", "is_major": "N"}, {"rank": "4", "name": "organizations", "value": "European Commission", "is_major": "N"}, {"rank": "5", "name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N"}, {"rank": "6", "name": "subject", "value": "Generic Brands and Products", "is_major": "N"}, {"rank": "7", "name": "subject", "value": "Antitrust Laws and Competition Issues", "is_major": "N"}]}